Cencora (COR) 10-Q 7 Feb 14 2014 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	3 Months Ended
	Dec. 31, 2013	Jan. 31, 2014	Mar. 31, 2013
Document and Entity Information [Abstract]	'	'	'
Entity Registrant Name	'AMERISOURCEBERGEN CORP	'	'
Entity Central Index Key	'0001140859	'	'
Document Type	'10-Q	'	'
Document Period End Date	31-Dec-13	'	'
Amendment Flag	'false	'	'
Document Fiscal Year Focus	'2014	'	'
Document Fiscal Period Focus	'Q1	'	'
Current Fiscal Year End Date	'--09-30	'	'
Entity Well-known Seasoned Issuer	'Yes	'	'
Entity Voluntary Filers	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Filer Category	'Large Accelerated Filer	'	'
Entity Public Float	'	'	$10,325,295,935
Entity Common Stock, Shares Outstanding	'	229,201,153	'

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2013	Sep. 30, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$347,465	$1,231,006
Accounts receivable, less allowances for returns and doubtful accounts: $351,241 at December 31, 2013 and $358,161 at September 30, 2013	6,214,193	6,051,920
Merchandise inventories	8,602,809	6,981,494
Prepaid expenses and other	63,878	129,231
Total current assets	15,228,345	14,393,651
Property and equipment, at cost:	'	'
Land	37,538	37,538
Buildings and improvements	328,883	324,150
Machinery, equipment and other	1,161,160	1,109,731
Total property and equipment	1,527,581	1,471,419
Less accumulated depreciation	-703,476	-667,858
Property and equipment, net	824,105	803,561
Goodwill and other intangible assets	3,501,341	3,499,713
Other assets	242,304	221,713
TOTAL ASSETS	19,796,095	18,918,638
Current liabilities:	'	'
Accounts payable	13,858,659	13,335,792
Accrued expenses and other	533,090	532,564
Short-term debt	423,000	0
Deferred income taxes	1,014,149	1,002,279
Total current liabilities	15,828,898	14,870,635
Long-term debt	1,396,776	1,396,606
Other liabilities	322,619	331,652
Stockholders' equity:	'	'
Common stock, $0.01 par value - authorized: 600,000,000 shares; issued and outstanding: 268,571,263 shares and 230,492,510 shares, at December 31, 2013, respectively, and 267,789,992 shares and 229,994,216 shares at September 30, 2013, respectively	2,686	2,678
Additional paid-in capital	2,327,268	2,360,992
Retained earnings	1,495,432	1,508,414
Accumulated other comprehensive loss	-41,076	-35,483
Treasury stock, at cost: 38,078,753 shares at December 31, 2013 and 37,795,776 shares at September 30, 2013	-1,536,508	-1,516,856
Total stockholders' equity	2,247,802	2,319,745
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$19,796,095	$18,918,638

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2013	Sep. 30, 2013
In Thousands, except Share data, unless otherwise specified
Current assets:	'	'
Allowances for returns and doubtful accounts	$351,241	$358,161
Stockholders' equity:	'	'
Common stock, par value	$0.01	$0.01
Common stock, shares authorized	600,000,000	600,000,000
Common stock, shares issued	268,571,263	267,789,992
Common stock, shares outstanding	230,492,510	229,994,216
Treasury stock, shares held	38,078,753	37,795,776

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Consolidated Statements of Operations [Abstract]	'	'
Revenue	$29,176,362	$21,059,811
Cost of goods sold	28,488,137	20,398,983
Gross profit	688,225	660,828
Operating expenses:	'	'
Distribution, selling, and administrative	364,060	320,700
Depreciation	37,319	31,873
Amortization	6,631	6,811
Warrants	116,297	0
Employee severance, litigation and other	4,302	2,004
Operating income	159,616	299,440
Other income	-597	-23
Interest expense, net	18,832	18,525
Income from continuing operations before income taxes	141,381	280,938
Income taxes	92,450	106,317
Income from continuing operations	48,931	174,621
Loss from discontinued operations, net of income taxes	-7,546	-6,010
Net income	$41,385	$168,611
Basic earnings per share:	'	'
Continuing operations	$0.21	$0.75
Discontinued operations	($0.03)	($0.03)
Rounding	$0	$0.01
Total	$0.18	$0.73
Diluted earnings per share:	'	'
Continuing operations	$0.21	$0.74
Discontinued operations	($0.03)	($0.03)
Rounding	($0.01)	$0
Total	$0.17	$0.71
Weighted average common shares outstanding:	'	'
Basic	230,277	232,361
Diluted	237,012	235,992
Cash dividends declared per share of common stock	$0.24	$0.21

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Income (Unaudited) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Statement of Income and Comprehensive Income [Abstract]	'	'
Net income	$41,385	$168,611
Other comprehensive (loss) income:	'	'
Net change in foreign currency translation adjustments	-5,442	-2,772
Other	-151	27
Total other comprehensive loss	-5,593	-2,745
Total comprehensive income	$35,792	$165,866

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (Unaudited) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
OPERATING ACTIVITIES	'	'
Net income	$41,385	$168,611
Loss from discontinued operations, net of income taxes	7,546	6,010
Income from continuing operations	48,931	174,621
Adjustments to reconcile income from continuing operations to net cash used in operating activities:	'	'
Depreciation, including amounts charged to cost of goods sold	37,887	33,594
Amortization, including amounts charged to interest expense	7,823	7,963
Provision (benefit) for doubtful accounts	1,688	-562
Provision for deferred income taxes	2,396	15,727
Warrants	116,297	0
Share-based compensation	11,226	9,326
Other	-2,675	531
Changes in operating assets and liabilities, excluding the effects of acquisitions:	'	'
Accounts receivable	-159,120	-429,125
Merchandise inventories	-1,626,618	-295,938
Prepaid expenses and other assets	43,659	14,673
Accounts payable, accrued expenses, and income taxes	523,117	211,423
Other liabilities	-708	839
Net cash used in operating activities - continuing operations	-996,097	-256,928
Net cash (used in) provided by operating activities - discontinued operations	-7,546	15,221
NET CASH USED IN OPERATING ACTIVITIES	-1,003,643	-241,707
INVESTING ACTIVITIES	'	'
Capital expenditures	-59,183	-56,286
Cost of acquired companies, net of cash acquired	-9,103	0
Other	83	23
Net cash used in investing activities - continuing operations	-68,203	-56,263
Net cash used in investing activities - discontinued operations	0	-5,116
NET CASH USED IN INVESTING ACTIVITIES	-68,203	-61,379
FINANCING ACTIVITIES	'	'
Borrowings under revolving and securitization credit facilities	522,500	796,000
Repayments under revolving and securitization credit facilities	-99,500	-796,000
Purchases of common stock	-19,652	-284,691
Exercises of stock options, including excess tax benefits of $11,631 and $8,632 in fiscal 2014 and 2013, respectively	32,326	39,750
Cash dividends on common stock	-54,367	-49,595
Purchases of capped call options	-192,995	0
Debt issuance costs and other	-7	-1,090
Net cash provided by (used in) financing activities - continuing operations	188,305	-295,626
Net cash used in financing activities - discontinued operations	0	-50,492
NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES	188,305	-346,118
DECREASE IN CASH AND CASH EQUIVALENTS	-883,541	-649,204
Cash and cash equivalents at beginning of period	1,231,006	1,066,608
CASH AND CASH EQUIVALENTS AT END OF PERIOD	$347,465	$417,404

Consolidated_Statements_of_Cas1

Consolidated Statements of Cash Flows (Unaudited) (Parenthetical) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
FINANCING ACTIVITIES	'	'
Excess tax benefit from the exercise of stock options	$11,631	$8,632

Summary_of_Significant_Account

Summary of Significant Accounting Policies	3 Months Ended
	Dec. 31, 2013
Summary of Significant Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies [Text Block]	'
	Note 1. Summary of Significant Accounting Policies
	Basis of Presentation
	The accompanying financial statements present the consolidated financial position, results of operations and cash flows of AmerisourceBergen Corporation and its wholly owned subsidiaries (the “Company”) as of the dates and for the periods indicated. All intercompany accounts and transactions have been eliminated in consolidation.
	The accompanying unaudited consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“GAAP”) for interim financial information, the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. In the opinion of management, all adjustments (consisting only of normal recurring accruals, except as otherwise disclosed herein) considered necessary to present fairly the financial position as of December 31, 2013 and the results of operations and cash flows for the interim periods ended December 31, 2013 and 2012 have been included. Certain information and footnote disclosures normally included in financial statements presented in accordance with U.S. GAAP, but which are not required for interim reporting purposes, have been omitted. The accompanying unaudited consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the fiscal year ended September 30, 2013.
	The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect amounts reported in the financial statements and accompanying notes. Actual amounts could differ from these estimated amounts.
	Certain reclassifications have been made to prior year amounts in order to conform to the current year presentation.

Discontinued_Operations

Discontinued Operations	3 Months Ended
	Dec. 31, 2013
Discontinued Operations [Abstract]	'
Discontinued Operations [Text Block]	'
	Note 2. Discontinued Operations
	In May 2013, the Company completed the divestiture of its packaging and clinical trials services business, AndersonBrecon (“AB”), and AmerisourceBergen Canada Corporation (“ABCC”). The Company has classified AB and ABCC's operating results, net of tax, as discontinued operations in the accompanying consolidated statements of operations for all periods presented. Prior to being classified within discontinued operations, AB was included in Other and ABCC was included in Pharmaceutical Distribution for segment reporting. AB and ABCC's revenue and loss before income taxes were as follows:
			Three months ended December 31,
		(in thousands)		2013		2012
		Revenue	$	-	$	474,230
		Loss before income taxes	$	-7,546	$	-2,053
	The loss before income taxes in the three months ended December 31, 2013 includes the impact of a final purchase price working capital adjustment related to the divestiture of ABCC.

Income_Taxes

Income Taxes	3 Months Ended
	Dec. 31, 2013
Income Taxes [Abstract]	'
Income Taxes [Text Block]	'
	Note 3. Income Taxes
	The Company files income tax returns in U.S. federal and state jurisdictions as well as various foreign jurisdictions. As of December 31, 2013, the Company had unrecognized tax benefits, defined as the aggregate tax effect of differences between tax return positions and the benefits recognized in the Company's financial statements, of $55.2 million ($38.9 million, net of federal benefit). If recognized, these tax benefits would reduce income tax expense and the effective tax rate. Included in this amount is $8.8 million of interest and penalties, which the Company records in income tax expense. During the three months ended December 31, 2013, unrecognized tax benefits decreased by $0.2 million. During the next 12 months, it is reasonably possible that state tax audit resolutions and the expiration of statutes of limitations could result in a reduction of unrecognized tax benefits by approximately $6.3 million.
	In March 2013, the Company issued Warrants (as defined in Note 6) in connection with various agreements and arrangements with Walgreen Co. (“Walgreens”) and Alliance Boots GmbH (“Alliance Boots”). As of the date of issuance, the Warrants were valued at $242.4 million, which approximates the amount that will be deductible for income tax purposes. The fair value of the Warrants as of December 31, 2013 was $895.2 million. The excess of the fair value as of December 31, 2013 over the initial value of $242.4 million is not tax deductible. As a result, the Company's current effective income tax rate, which includes the impact of the Warrants, is higher than its historical rate.

Goodwill_and_Other_Intangible_

Goodwill and Other Intangible Assets	3 Months Ended
	Dec. 31, 2013
Goodwill and Other Intangible Assets [Abstract]	'
Goodwill and Other Intangible Assets [Text Block]	'
	Note 4. Goodwill and Other Intangible Assets
	Following is a summary of the changes in the carrying value of goodwill, by reportable segment, for the three months ended December 31, 2013 (in thousands):
				Pharmaceutical Distribution			Other			Total
		Goodwill at September 30, 2013		$	2,400,926		$	544,044		$	2,944,970
		Goodwill recognized in connection with acquisition			-			5,515			5,515
		Foreign currency translation			-			-626			-626
		Goodwill at December 31, 2013		$	2,400,926		$	548,933		$	2,949,859
	Following is a summary of other intangible assets (in thousands):
		31-Dec-13									30-Sep-13
		Gross Carrying Amount			Accumulated Amortization			Net Carrying Amount			Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount
	Indefinite-lived
	intangibles - trade
	names	$	343,822		$	-		$	343,822		$	343,892	$	-	$	343,892
	Finite-lived
	intangibles:
	Customer
	relationships		268,592			-85,319			183,273			265,810		-80,767		185,043
	Other		69,861			-45,474			24,387			69,350		-43,542		25,808
	Total other intangible
	assets	$	682,275		$	-130,793		$	551,482		$	679,052	$	-124,309	$	554,743
	Amortization expense for other intangible assets was $6.6 million and $6.8 million in the three months ended December 31, 2013 and 2012, respectively. Amortization expense for other intangible assets is estimated to be $26.0 million in fiscal 2014, $22.2 million in fiscal 2015, $21.3 million in fiscal 2016, $17.6 million in fiscal 2017, $15.3 million in fiscal 2018, and $111.9 million thereafter.

Debt

Debt	3 Months Ended
	Dec. 31, 2013
Debt [Abstract]	'
Debt [Text Block]	'
	Note 5. Debt
	Debt consisted of the following (in thousands):
			December 31,		September 30,
			2013		2013
		Receivables securitization facility due 2016	$	300,000	$	-
		Multi-currency revolving credit facility due 2018		78,000		-
		Revolving credit note		45,000		-
		$500,000, 5 7/8% senior notes due 2015		499,444		499,377
		$400,000, 4 7/8% senior notes due 2019		397,881		397,803
		$500,000, 3 1/2% senior notes due 2021		499,451		499,426
		Total debt	$	1,819,776	$	1,396,606
	The Company has a $1.4 billion multi-currency senior unsecured revolving credit facility, which is scheduled to expire in July 2018 (the “Multi-Currency Revolving Credit Facility”), with a syndicate of lenders. Interest on borrowings under the Multi-Currency Revolving Credit Facility accrues at specified rates based on the Company's debt rating and ranges from 68 basis points to 130 basis points over LIBOR / EURIBOR / Bankers Acceptance Stamping Fee, as applicable (90 basis points over LIBOR / EURIBOR / Bankers Acceptance Stamping Fee at December 31, 2013). Additionally, interest on borrowings denominated in Canadian dollars may accrue at the greater of the Canadian prime rate or the CDOR rate. The Company pays facility fees to maintain the availability under the Multi-Currency Revolving Credit Facility at specified rates based on its debt rating, ranging from 7 basis points to 20 basis points, annually, of the total commitment (10 basis points at December 31, 2013). The Company may choose to repay or reduce its commitments under the Multi-Currency Revolving Credit Facility at any time. The Multi-Currency Revolving Credit Facility contains covenants, including compliance with a financial leverage ratio test, as well as others that impose limitations on, among other things, indebtedness of excluded subsidiaries and asset sales, with which the Company was compliant as of December 31, 2013.
	The Company has a commercial paper program whereby it may from time to time issue short-term promissory notes in an aggregate amount of up to $700 million at any one time. Amounts available under the program may be borrowed, repaid, and re-borrowed from time to time. The maturities on the notes will vary, but may not exceed 365 days from the date of issuance. The notes will bear interest rates, if interest bearing, or will be sold at a discount from their face amounts. The commercial paper program does not increase the Company's borrowing capacity as it is fully backed by the Company's Multi-Currency Revolving Credit Facility. There were no borrowings outstanding under the commercial paper program at December 31, 2013.
	The Company has a $950 million receivables securitization facility (“Receivables Securitization Facility”), which is scheduled to expire in June 2016. The Company has available to it an accordion feature whereby the commitment on the Receivables Securitization Facility may be increased by up to $250 million, subject to lender approval, for seasonal needs during the December and March quarters. During December 2013, the Company increased the availability of the Receivables Securitization Facility by $250 million under the accordion feature. Interest rates are based on prevailing market rates for short-term commercial paper or LIBOR plus a program fee of 75 basis points. The Company pays an unused fee of 40 basis points, annually, to maintain the availability under the Receivables Securitization Facility. The Receivables Securitization Facility contains similar covenants to the Multi-Currency Revolving Credit Facility, with which the Company was compliant as of December 31, 2013.
	The Company has an uncommitted, unsecured line of credit available to it pursuant to a revolving credit note (“Revolving Credit Note”). The Revolving Credit Note provides the Company with the ability to request short-term unsecured revolving credit loans from time to time in a principal amount not to exceed $45 million at any time outstanding.

Stockholders_Equity_and_Earnin

Stockholders' Equity and Earnings per Share	3 Months Ended
	Dec. 31, 2013
Stockholders' Equity and Earnings per Share [Abstract]	'
Stockholders' Equity and Earnings per Share	'
	Note 6. Stockholders' Equity and Earnings per Share
	In November 2013, the Company's board of directors increased the quarterly cash dividend by 12% from $0.21 per share to $0.235 per share.
	In November 2012, the Company's board of directors authorized a program allowing the Company to purchase up to $750 million of its outstanding shares of common stock, subject to market conditions. During the three months ended December 31, 2013, the Company purchased 0.3 million shares of its common stock for a total of $19.6 million. The Company had $343.4 million of availability remaining under this share repurchase program as of December 31, 2013. In August 2013, the Company's board of directors authorized a new program allowing the Company to purchase up to an additional $750 million of its outstanding shares of common stock, subject to market conditions.
	In March 2013, the Company, Walgreens, and Alliance Boots entered into various agreements and arrangements pursuant to which Walgreens and Alliance Boots together were granted the right to purchase a minority equity position in the Company, beginning with the right, but not the obligation, to purchase up to 19,859,795 shares of the Company's common stock (approximately 7% of the Company's common stock, on a fully diluted basis as of the date of issuance, assuming the exercise in full of the Warrants, as defined below) in open market transactions. In connection with these arrangements, Walgreens Pharmacy Strategies, LLC, a wholly owned subsidiary of Walgreens, was issued (a) a warrant to purchase up to 11,348,456 shares of the Company's common stock at an exercise price of $51.50 per share exercisable during a six month period beginning in March 2016, and (b) a warrant to purchase up to 11,348,456 shares of the Company's common stock at an exercise price of $52.50 per share exercisable during a six-month period beginning in March 2017 and Alliance Boots Luxembourg S.à.r.l., a wholly owned subsidiary of Alliance Boots, was issued (a) a warrant to purchase up to 11,348,456 shares of the Company's common stock at an exercise price of $51.50 per share exercisable during a six-month period beginning in March 2016 and (b) a warrant to purchase up to 11,348,456 shares of the Company's common stock at an exercise price of $52.50 per share exercisable during a six-month period beginning in March 2017 (collectively, the “Warrants”).
	The Company valued these Warrants as of March 18, 2013 (date of issuance) and revised the valuation each subsequent quarter. As of December 31, 2013, the Warrants with an exercise price of $51.50 were valued at $19.49 per share and the Warrants with an exercise price of $52.50 were valued at $19.95 per share. In total, the Warrants were valued at $895.2 million as of December 31, 2013. Refer to “Critical Accounting Policies and Estimates – Warrants” in the Company's Annual Report on Form 10-K for the fiscal year ended September 30, 2013 for a more detailed description of the accounting for the Warrants.
	The Company intends to mitigate the potentially dilutive effect that the exercise of the Warrants could have by hedging a portion of its future obligation to deliver common stock with a financial institution and repurchasing additional shares of its common stock for the Company's own account over time. In June 2013, the Company commenced its hedging strategy by entering into a contract with a financial institution pursuant to which it has executed a series of issuer capped call option transactions (“Capped Calls”). The Capped Calls give the Company the right to buy 60% of the shares of its common stock subject to the Warrants at specified prices at maturity, should the Warrants be exercised in 2016 and 2017 and assuming the Company's future share price does not exceed the “cap” price in the Capped Calls. If the Company's share price exceeds the “cap” price in the Capped Calls at the time the Warrants are exercised, the number of shares that will be delivered to the Company under the Capped Calls will be reduced, and accordingly, will cover less than 60% of the shares of common stock subject to the Warrants.
	Through September 30, 2013, the Company purchased Capped Calls on 15.3 million shares of its common stock for a total premium of $163.4 million. During the three months ended December 31, 2013, the Company purchased Capped Calls on an additional 11.3 million shares of its common stock for a total premium of $193.5 million. The Capped Calls permit the Company to acquire shares of its common stock at strike prices of $51.50 and $52.50 and have expiration dates ranging from February 2016 through October 2017. The Capped Calls permit net share settlement, which is limited by caps on the market price of the Company's common stock. The Company has accounted for the Capped Calls as equity contracts and therefore, the above premiums were recorded as a reduction to paid-in capital.
	Basic earnings per share is computed on the basis of the weighted average number of shares of common stock outstanding during the periods presented. Diluted earnings per share is computed on the basis of the weighted average number of shares of common stock outstanding during the periods presented plus the dilutive effect of stock options, restricted stock, restricted stock units, and the Warrants.
			Three months ended
			December 31,
		(in thousands)	2013	2012
		Weighted average common shares outstanding - basic	230,277	232,361
		Dilutive effect of stock options, restricted
		stock, and restricted stock units	5,106	3,631
		Dilutive effect of Warrants	1,629	-
		Weighted average common shares outstanding - diluted	237,012	235,992
	The potentially dilutive stock options that were antidilutive for the three months ended December 31, 2013 and 2012 were 1.2 million and 1.9 million, respectively.

Legal_Matters_and_Contingencie

Legal Matters and Contingencies	3 Months Ended
	Dec. 31, 2013
Legal Matters and Contingencies [Abstract]	'
Legal Matters and Contingencies [Text Block]	'
	Note 7. Legal Matters and Contingencies
	In the ordinary course of its business, the Company becomes involved in lawsuits, administrative proceedings, government subpoenas, and government investigations, including antitrust, commercial, environmental, product liability, intellectual property, regulatory, employment discrimination, and other matters. Significant damages or penalties may be sought from the Company in some matters, and some matters may require years for the Company to resolve. The Company establishes reserves based on its periodic assessment of estimates of probable losses. There can be no assurance that an adverse resolution of one or more matters during any subsequent reporting period will not have a material adverse effect on the Company's results of operations for that period or on the Company's financial condition.
	Qui Tam
	The qui tam provisions of the federal civil False Claims Act and various state and local civil False Claims Acts permit a private person, known as a "relator" or whistleblower, to file civil actions under these statutes on behalf of the federal, state and local governments. Such cases may involve allegations around the marketing, sale and/or purchase of pharmaceutical products. Qui tam complaints are initially filed by the relator under seal (or on a confidential basis) and the filing of the complaint imposes obligations on government authorities to investigate the allegations in the complaint and to determine whether or not to intervene in the action. Qui tam complaints remain sealed until the court in which the case was filed orders otherwise.
	The Company has learned that there are filings in one or more federal district courts, including a qui tam complaint filed by one of its former employees, that are under seal and may involve allegations against the Company (and/or subsidiaries or businesses of the Company, including its group purchasing organization for oncologists and its oncology distribution business) relating to its distribution of certain pharmaceutical products to providers. The Company and AmerisourceBergen Specialty Group (“ABSG”) have also received subpoenas from the United States Attorney's Office for the Eastern District of New York ("USAO") requesting production of documents and information relating to ABSG's oncology distribution center and former pharmacy in Dothan, Alabama, its group purchasing organization for oncologists, and intercompany transfers of certain oncology products, which the Company believes could be related to one or more of the qui tam actions that remain under seal. The Company is in the process of responding to the subpoenas and is cooperating fully with the USAO. The Company cannot predict the outcome of any pending action in which any AmerisourceBergen entity is or may become a defendant.
	Subpoenas from United States Attorney's Offices
	In fiscal 2012, the Company's subsidiary, AmerisourceBergen Drug Corporation (“ABDC”), received a subpoena from the United States Attorney's Office in New Jersey (the "USAO") in connection with a grand jury proceeding requesting documents concerning ABDC's program for controlling and monitoring diversion of controlled substances into channels other than for legitimate medical, scientific, and industrial purposes. ABDC also received a subpoena from the Drug Enforcement Administration ("DEA") in connection with the matter. In addition to requesting information on ABDC's diversion control program generally, the subpoenas also request documents concerning specific customers' purchases of controlled substances. ABDC has responded to the subpoenas and is cooperating fully with the USAO and the DEA. On August 30, 2013, ABDC received a second subpoena from the USAO requesting additional information related to the documents produced in response to the first subpoena, as well as information regarding additional specific customers' purchases of controlled substances. On December 31, 2013, ABDC received a third subpoena from the USAO requesting additional information related to electronically stored information. The Company cannot predict the outcome of this matter.
	In fiscal 2013, the Company or ABDC has also received similar subpoenas from the United States Attorney's Office in the District of Kansas and the United States Attorney's Office in the Northern District of Ohio in connection with grand jury proceedings requesting documents in concerning ABDC's program for controlling and monitoring diversion of controlled substances into channels other than for legitimate medical, scientific and industrial purposes. As in the New Jersey matter described above, in addition to requesting information on ABDC's diversion control program generally, the subpoenas also request documents concerning specific customers' purchases of controlled substances. The Company is in the process of responding to the subpoenas and cannot predict the outcome of these matters.
	West Virginia Complaint
	On June 26, 2012, the Attorney General of the State of West Virginia ("West Virginia") filed a complaint (the "Complaint") in the Circuit Court of Boone County, West Virginia, against a number of pharmaceutical wholesale distributors, including the Company's subsidiary, ABDC, alleging, among other things, that the distributors failed to provide effective controls and procedures to guard against diversion of controlled substances for illegitimate purposes in West Virginia. The Complaint also alleges that the distributors acted negligently by distributing controlled substances to pharmacies that serve individuals who abuse prescription pain medication and were unjustly enriched by such conduct, violated consumer credit and protection laws, created a public nuisance, and violated state antitrust laws in connection with the distribution of controlled substances. West Virginia is seeking injunctive relief to enjoin alleged violations of state regulations requiring suspicious order monitoring and reporting and to require defendants to fund a medical monitoring treatment program. The Complaint also seeks a jury trial to determine any losses and damages sustained by West Virginia as a result of the defendants' alleged conduct. On July 26, 2012, one of the defendants, J.M. Smith Corporation d/b/a Smith Drug Company, filed a Notice of Removal from the Circuit Court of Boone County, West Virginia to the United States District Court for the Southern District of West Virginia, and ABDC and all other defendants filed Consents to Removal. On August 27, 2012, West Virginia filed a Motion to Remand, to which J.M. Smith Corporate d/b/a Smith Drug Company, joined by all other defendants, filed a reply. On March 27, 2013, the Court granted West Virginia's Motion to Remand and West Virginia notified the parties that they intended to file an amended complaint. In advance of filing an amended complaint, West Virginia served discovery requests and subsequently filed a motion to compel. After responding to West Virginia's motion to compel and oral argument, defendants were ordered to provide limited responses. On January 2, 2014, West Virginia filed an amended complaint, which removed the claims for unjust enrichment, medical monitoring and antitrust violations. The Company cannot predict the outcome of this matter.

Litigation_Settlements

Litigation Settlements	3 Months Ended
	Dec. 31, 2013
Litigation Settlements [Abstract]	'
Litigation Settlements [Text Block]	'
	Note 8. Litigation Settlements
	Antitrust Settlements
	Numerous class action lawsuits have been filed against certain brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the market. The Company has not been named a plaintiff in any of these class actions, but has been a member of the direct purchasers' class (i.e., those purchasers who purchase directly from these pharmaceutical manufacturers). None of the class actions have gone to trial, but some have settled in the past with the Company receiving proceeds from the settlement funds. The Company recognized gains of $21.0 million and $12.3 million relating to the above-mentioned class action lawsuits in the three months ended December 2013 and 2012, respectively. These gains, which are net of attorney fees and estimated payments due to other parties, were recorded as reductions to cost of goods sold in the Company's consolidated statements of operations.

Fair_Value_of_Financial_Instru

Fair Value of Financial Instruments	3 Months Ended
	Dec. 31, 2013
Fair Value of Financial Instruments [Abstract]	'
Fair Value of Financial Instruments [Text Block]	'
	Note 9. Fair Value of Financial Instruments
	The recorded amounts of the Company's cash and cash equivalents, accounts receivable, accounts payable, and short-term debt at December 31, 2013 and September 30, 2013 approximate fair value based upon the relatively short-term nature of these financial instruments. The recorded amount of long-term debt and the corresponding fair value as of December 31, 2013 were $1,396.8 million and $1,489.7 million, respectively. The recorded amount of long-term debt and the corresponding fair value as of September 30, 2013 were $1,396.6 million and $1,502.0 million, respectively. The fair values of debt were determined based on quoted market prices, otherwise known as Level 2 inputs.

Business_Segment_Information

Business Segment Information	3 Months Ended
	Dec. 31, 2013
Business Segment Information [Abstract]	'
Business Segment Information [Text Block]	'
	Note 10. Business Segment Information
	The Company is organized based upon the products and services it provides to its customers. The Company's operations are comprised of the Pharmaceutical Distribution reportable segment and Other. The Pharmaceutical Distribution reportable segment consists of the AmerisourceBergen Drug Corporation (“ABDC”) and AmerisourceBergen Specialty Group (“ABSG”) operating segments. Other consists of the AmerisourceBergen Consulting Services (“ABCS”) and World Courier Group, Inc. (“World Courier”) operating segments.
	The following tables illustrate reportable segment information for the three months ended December 31, 2013 and 2012 (in thousands):
			Revenue
			Three months ended
			December 31,
			2013		2012
		Pharmaceutical Distribution	$	28,622,591	$	20,599,048
		Other		604,132		505,050
		Intersegment eliminations		-50,361		-44,287
		Revenue	$	29,176,362	$	21,059,811
	Intersegment eliminations primarily represent the elimination of certain ABCS sales to the Pharmaceutical Distribution reportable segment.
			Operating Income
			Three months ended
			December 31,
			2013		2012
		Pharmaceutical Distribution	$	286,782	$	266,677
		Other		35,950		29,725
		Total segment operating income		322,732		296,402
		Gain on antitrust litigation settlements		21,023		12,308
		LIFO expense		-57,582		-1,167
		Acquisition related intangibles
		amortization		-5,958		-6,099
		Warrant expense		-116,297		-
		Employee severance, litigation and other		-4,302		-2,004
		Operating income		159,616		299,440
		Other income		-597		-23
		Interest expense, net		18,832		18,525
		Income from continuing operations
		before income taxes	$	141,381	$	280,938
	Segment operating income is evaluated by the chief operating decision maker for the Company before gains on antitrust litigation settlements; LIFO expense; acquisition related intangibles amortization; Warrant expense; employee severance, litigation and other; other income; and interest expense, net. All corporate office expenses are allocated to ABDC and ABSG within the Pharmaceutical Distribution reportable segment and to ABCS and World Courier within Other. Management believes that evaluating segment performance excluding the above items is meaningful because it provides insight with respect to operating results of the Company.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Dec. 31, 2013
Summary of Significant Accounting Policies [Abstract]	'
Consolidation Policy [Policy Text Block]	'
	The accompanying financial statements present the consolidated financial position, results of operations and cash flows of AmerisourceBergen Corporation and its wholly owned subsidiaries (the “Company”) as of the dates and for the periods indicated. All intercompany accounts and transactions have been eliminated in consolidation.
Basis of Accounting [Policy Text Block]	'
	The accompanying unaudited consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“GAAP”) for interim financial information, the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. In the opinion of management, all adjustments (consisting only of normal recurring accruals, except as otherwise disclosed herein) considered necessary to present fairly the financial position as of December 31, 2013 and the results of operations and cash flows for the interim periods ended December 31, 2013 and 2012 have been included. Certain information and footnote disclosures normally included in financial statements presented in accordance with U.S. GAAP, but which are not required for interim reporting purposes, have been omitted. The accompanying unaudited consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the fiscal year ended September 30, 2013.
Use of Estimates, Policy [Policy Text Block]	'
	The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect amounts reported in the financial statements and accompanying notes. Actual amounts could differ from these estimated amounts.
Reclassifications [Policy Text Block]	'
	Certain reclassifications have been made to prior year amounts in order to conform to the current year presentation.

Discontinued_Operations_Tables

Discontinued Operations (Tables)	3 Months Ended
	Dec. 31, 2013
Discontinued Operations [Abstract]	'
Schedule of Disposal Groups Inlcuding Discontinued Operations Income Statement Balance Sheet and Additional Disclosures [Text Block]	'
			Three months ended December 31,
		(in thousands)		2013		2012
		Revenue	$	-	$	474,230
		Loss before income taxes	$	-7,546	$	-2,053

Goodwill_and_Other_Intangible_1

Goodwill and Other Intangible Assets (Tables)	3 Months Ended
	Dec. 31, 2013
Goodwill and Other Intangible Assets [Abstract]	'
Schedule of Goodwill [Text Block]	'
				Pharmaceutical Distribution			Other			Total
		Goodwill at September 30, 2013		$	2,400,926		$	544,044		$	2,944,970
		Goodwill recognized in connection with acquisition			-			5,515			5,515
		Foreign currency translation			-			-626			-626
		Goodwill at December 31, 2013		$	2,400,926		$	548,933		$	2,949,859
Schedule of Other Intangible Assets [Text Block]	'
		31-Dec-13									30-Sep-13
		Gross Carrying Amount			Accumulated Amortization			Net Carrying Amount			Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount
	Indefinite-lived
	intangibles - trade
	names	$	343,822		$	-		$	343,822		$	343,892	$	-	$	343,892
	Finite-lived
	intangibles:
	Customer
	relationships		268,592			-85,319			183,273			265,810		-80,767		185,043
	Other		69,861			-45,474			24,387			69,350		-43,542		25,808
	Total other intangible
	assets	$	682,275		$	-130,793		$	551,482		$	679,052	$	-124,309	$	554,743

Debt_Tables

Debt (Tables)	3 Months Ended
	Dec. 31, 2013
Debt [Abstract]	'
Schedule Of Debt Instruments Text Block	'
			December 31,		September 30,
			2013		2013
		Receivables securitization facility due 2016	$	300,000	$	-
		Multi-currency revolving credit facility due 2018		78,000		-
		Revolving credit note		45,000		-
		$500,000, 5 7/8% senior notes due 2015		499,444		499,377
		$400,000, 4 7/8% senior notes due 2019		397,881		397,803
		$500,000, 3 1/2% senior notes due 2021		499,451		499,426
		Total debt	$	1,819,776	$	1,396,606

Stockholders_Equity_and_Earnin1

Stockholders' Equity and Earnings Per Share (Tables)	3 Months Ended
	Dec. 31, 2013
Stockholders' Equity and Earnings per Share [Abstract]	'
Schedule of Weighted Average Number of Shares [Table Text Block]	'
			Three months ended
			December 31,
		(in thousands)	2013	2012
		Weighted average common shares outstanding - basic	230,277	232,361
		Dilutive effect of stock options, restricted
		stock, and restricted stock units	5,106	3,631
		Dilutive effect of Warrants	1,629	-
		Weighted average common shares outstanding - diluted	237,012	235,992

Business_Segment_Information_T

Business Segment Information (Tables)	3 Months Ended
	Dec. 31, 2013
Reconciliation from Segment Totals to Consolidated [Abstract]	'
Reconciliation of Revenue from Segments to Consolidated [Table Text Block]	'
			Revenue
			Three months ended
			December 31,
			2013		2012
		Pharmaceutical Distribution	$	28,622,591	$	20,599,048
		Other		604,132		505,050
		Intersegment eliminations		-50,361		-44,287
		Revenue	$	29,176,362	$	21,059,811
Schedule of Segment Reporting Information, by Segment [Table Text Block]	'
			Operating Income
			Three months ended
			December 31,
			2013		2012
		Pharmaceutical Distribution	$	286,782	$	266,677
		Other		35,950		29,725
		Total segment operating income		322,732		296,402
		Gain on antitrust litigation settlements		21,023		12,308
		LIFO expense		-57,582		-1,167
		Acquisition related intangibles
		amortization		-5,958		-6,099
		Warrant expense		-116,297		-
		Employee severance, litigation and other		-4,302		-2,004
		Operating income		159,616		299,440
		Other income		-597		-23
		Interest expense, net		18,832		18,525
		Income from continuing operations
		before income taxes	$	141,381	$	280,938

Discontinued_Operations_Detail

Discontinued Operations (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Discontinued Operations [Abstract]	'	'
disposal group including discontinued operation revenue	$0	$474,230
disposal group including discontinued operation operating income	($7,546)	($2,053)

Income_Taxes_Details

Income Taxes (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Mar. 18, 2013
Current Income Tax Expense (Benefit), Continuing Operations [Abstract]	'	'
Unrecognized Tax Benefits	$55.20	'
Unrecognized Tax Benefits That Would Impact Effective Tax Rate	38.9	'
Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued	8.8	'
Unrecognized Tax Benefits Period Increase Decrease	0.2	'
Significant Change In Unrecognized Tax Benefits Is Reasonably Possible Amount Of Unrecorded Benefit	6.3	'
Full Value of Warrants	$895.20	$242.40

Goodwill_and_Other_Intangible_2

Goodwill and Other Intangible Assets (Details) (USD $)	3 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Sep. 30, 2013
Goodwill [Line Items]	'	'	'
Goodwill at September 30, 2013	$2,944,970,000	'	'
Goodwill, Acquired During Period	5,515,000	'	'
Goodwill, Translation Adjustments	-626,000	'	'
Goodwill at December 31, 2013	2,949,859,000	'	'
Indefinite-lived intangibles-trade names	343,822,000	'	343,892,000
Finite Lived Intangible Assets [Line Items]	'	'	'
Intangible Assets Gross Excluding Goodwill	682,275,000	'	679,052,000
Intangible Assets Accumulated Amortization Excluding Goodwill	130,793,000	'	124,309,000
Intangible Assets Net Excluding Goodwill	551,482,000	'	554,743,000
Amortization of Intangible Assets	6,631,000	6,811,000	'
Future Amortization Expense Year One	26,000,000	'	'
Future Amortization Expense Year Two	22,200,000	'	'
Future Amortization Expense Year Three	21,300,000	'	'
Future Amortization Expense Year Four	17,600,000	'	'
Future Amortization Expense Year Five	15,300,000	'	'
Future Amortization Expense, after Year Five	111,900,000	'	'
Customer Relationships [Member]	'	'	'
Finite Lived Intangible Assets [Line Items]	'	'	'
Finite Lived Intangible Assets Gross	268,592,000	'	265,810,000
Finite Lived Intangible Assets Accumulated Amortization	85,319,000	'	80,767,000
Finite Lived Intangible Assets Net	183,273,000	'	185,043,000
Other Finite Lived Intangibles [Member]	'	'	'
Finite Lived Intangible Assets [Line Items]	'	'	'
Finite Lived Intangible Assets Gross	69,861,000	'	69,350,000
Finite Lived Intangible Assets Accumulated Amortization	45,474,000	'	43,542,000
Finite Lived Intangible Assets Net	24,387,000	'	25,808,000
Pharmaceutical Distribution [Member]	'	'	'
Goodwill [Line Items]	'	'	'
Goodwill at September 30, 2013	2,400,926,000	'	'
Goodwill, Acquired During Period	0	'	'
Goodwill, Translation Adjustments	0	'	'
Goodwill at December 31, 2013	2,400,926,000	'	'
Other Segment [Member]	'	'	'
Goodwill [Line Items]	'	'	'
Goodwill at September 30, 2013	544,044,000	'	'
Goodwill, Acquired During Period	5,515,000	'	'
Goodwill, Translation Adjustments	-626,000	'	'
Goodwill at December 31, 2013	$548,933,000	'	'

Debt_Details

Debt (Details) (USD $)	3 Months Ended
	Dec. 31, 2013	Sep. 30, 2013
Debt Instrument [Line Items]	'	'
Short-term debt	$423,000,000	$0
Long Term Debt	1,396,776,000	1,396,606,000
Debt and Capital Lease Obligations	1,819,776,000	1,396,606,000
Receivables Securitization Facility [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt Instrument, Maturity Date, Description	'June 2016	'
Short-term debt	300,000,000	0
Line of Credit Facility, Maximum Borrowing Capacity	950,000,000	'
Line of Credit Facility, Interest Rate Description	'prevailing market rates for short-term commercial paper or LIBOR plus a program fee of 75 basis points	'
Line of Credit Facility, Covenant Terms	'The Receivables Securitization Facility contains similar covenants to the Multi-Currency Revolving Credit Facility, with which the Company was compliant as of December 31, 2013	'
Debt Instrument Ability to Increase Commitment Subject to Lender Approval	'the commitment on the Receivables Securitization Facility may be increased by up to $250 million, subject to lender approval, for seasonal needs during the December and March quarters	'
Debt Instrument Capacity Increase Due to Execution of Accordion Feature	250,000,000	'
Line of Credit Facility Unused Capacity Commitment Fee Percentage	0.40%	'
Multi Currency Revolving Credit Facility [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt Instrument, Maturity Date, Description	'July 2018	'
Short-term debt	78,000,000	0
Line of Credit Facility, Maximum Borrowing Capacity	1,400,000,000	'
Line of Credit Facility, Interest Rate Description	'68 basis points to 130 basis points over LIBOR / EURIBOR / Bankers Acceptance Stamping Fee	'
Debt Instrument Fee Rate Effective Percentage Rate Range	'7 basis points to 20 basis points, annually, of the total commitment	'
Line of Credit Facility, Covenant Terms	'The Multi-Currency Revolving Credit Facility contains covenants, including compliance with a financial leverage ratio test, as well as others that impose limitations on, among other things, indebtedness of excluded subsidiaries and asset sales, with which the Company was compliant as of December 31, 2013.	'
Debt Interest Rate at Period End	'90 basis points over LIBOR / EURIBOR / Bankers Acceptance Stamping Fee	'
Interest Rate Option on Canadian Borrowings	'the Canadian prime rate or the CDOR rate	'
Line of Credit Facility Commitment Fee Percentage	0.10%	'
Senior Notes Due 2015 [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt Instrument, Face Amount	500,000,000	'
Debt Instrument, Interest Rate, Stated Percentage	5.88%	'
Debt Instrument, Maturity Date, Description	'2015	'
Long Term Debt	499,444,000	499,377,000
Senior Notes Due 2019 [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt Instrument, Face Amount	400,000,000	'
Debt Instrument, Interest Rate, Stated Percentage	4.88%	'
Debt Instrument, Maturity Date, Description	'2019	'
Long Term Debt	397,881,000	397,803,000
Senior Notes Due 2021 [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt Instrument, Face Amount	500,000,000	'
Debt Instrument, Interest Rate, Stated Percentage	3.50%	'
Debt Instrument, Maturity Date, Description	'2021	'
Long Term Debt	499,451,000	499,426,000
Revolving Credit Note [Member]	'	'
Debt Instrument [Line Items]	'	'
Short-term debt	45,000,000	0
Line of Credit Facility, Maximum Borrowing Capacity	45,000,000	'
Commercial Paper [Member]	'	'
Debt Instrument [Line Items]	'	'
Short-term debt	0	'
Line of Credit Facility, Maximum Borrowing Capacity	$700,000,000	'
Short-term Debt, Terms	'The Company has a commercial paper program whereby it may from time to time issue short-term promissory notes in an aggregate amount of up to $700 million at any one time. Amounts available under the program may be borrowed, repaid, and re-borrowed from time to time. The maturities on the notes will vary, but may not exceed 365 days from the date of issuance. The notes will bear interest rates, if interest bearing, or will be sold at a discount from their face amounts. The commercial paper program does not increase the Company's borrowing capacity as it is fully backed by the Company's Multi-Currency Revolving Credit Facility.	'

Stockholders_Equity_and_Earnin2

Stockholders' Equity and Earnings per Share (Details) (USD $)

1 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

1 Months Ended

3 Months Ended

1 Months Ended

In Millions, except Share data, unless otherwise specified

Nov. 30, 2012

Dec. 31, 2013

Dec. 31, 2012

Sep. 30, 2013

Mar. 31, 2013

Mar. 18, 2013

Dec. 31, 2013

Dec. 31, 2013

Mar. 31, 2013

Mar. 31, 2013

Mar. 31, 2013

Mar. 31, 2013

Nov. 30, 2012

Dec. 31, 2013

Aug. 31, 2013

First Group of Tranches [Member]

Second Group of Tranches [Member]

Walgreens Warrant 1 [Member]

Walgreens Warrant 2 [Member]

Alliance Boots Warrant 1 [Member]

Alliance Boots Warrant 2 [Member]

November 2012 Share Repurchase Program [Member]

November 2012 Share Repurchase Program [Member]

August 2013 Share Repurchase Program [Member]

Stockholders' Equity and Earnings per Share [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Dividend Increase Percentage

12.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock, Dividends, Per Share, Declared

$0.24

$0.24

$0.21

'

'

'

'

'

'

'

'

'

'

'

'

Basic

'

230,277,000

232,361,000

'

'

'

'

'

'

'

'

'

'

'

'

Incremental Common Shares Attributable To Share Based Payment Arrangements

'

5,106,000

3,631,000

'

'

'

'

'

'

'

'

'

'

'

'

Incremental Common Shares Attributable to Call Options and Warrants

'

1,629,000

0

'

'

'

'

'

'

'

'

'

'

'

'

Diluted

'

237,012,000

235,992,000

'

'

'

'

'

'

'

'

'

'

'

'

Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount

'

1,200,000

1,900,000

'

'

'

'

'

'

'

'

'

'

'

'

Equity, Class of Treasury Stock [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Repurchase Program, Authorized Amount

'

'

'

'

'

'

'

'

'

'

'

'

$750

'

$750

Treasury Stock Value Acquired Cost Method

'

'

'

'

'

'

'

'

'

'

'

'

'

19.6

'

Treasury Stock, Shares, Acquired

'

'

'

'

'

'

'

'

'

'

'

'

'

300,000

'

Stock Repurchase Program Remaining Authorized Amount

'

'

'

'

'

'

'

'

'

'

'

'

'

343.4

'

Class of Warrant or Right [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Date from which Warrants or Rights are Exercisable

'

'

'

'

'

'

'

'

1-Mar-16

1-Mar-17

1-Mar-16

1-Mar-17

'

'

'

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

'

'

'

'

'

'

'

'

11,348,456

11,348,456

11,348,456

11,348,456

'

'

'

Class of Warrant or Right, Exercise Price of Warrants or Rights

'

'

'

'

'

'

'

'

$51.50

$52.50

$51.50

$52.50

'

'

'

Shares to Which Framework Agreement Allows Open Market Purchases

'

'

'

'

19,859,795

'

'

'

'

'

'

'

'

'

'

Percentage of Common Stock Purchases in Open Market Granted under Framework Agreement

'

'

'

'

0.07

'

'

'

'

'

'

'

'

'

'

Fair Value per Share of First Tranche of Warrants

'

$19.49

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair Value per Share of Second Tranche of Warrants

'

$19.95

'

'

'

'

'

'

'

'

'

'

'

'

'

Full Value of Warrants

'

895.2

'

'

'

242.4

'

'

'

'

'

'

'

'

'

Forward Contract Indexed to Issuer's Equity [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Forward Contract Indexed to Issuer's Equity, Forward Rate

'

'

'

'

'

'

$51.50

$52.50

'

'

'

'

'

'

'

Derivative, Cost of Hedge

'

$193.50

'

$163.40

'

'

'

'

'

'

'

'

'

'

'

Percentage of Warrant Dilution Intended to be Hedged with Contract

'

60.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares Covered Under Derviative Purchases

'

11,300,000

'

15,300,000

'

'

'

'

'

'

'

'

'

'

'

Litigation_Settlements_Details

Litigation Settlements (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Litigation Settlements [Abstract]	'	'
Antitrust Settlements Gain	$21,023	$12,308

Financial_Instruments_Details

Financial Instruments (Details) (USD $)	Dec. 31, 2013	Sep. 30, 2013
Fair Value of Financial Instruments [Abstract]	'	'
Long Term Debt	$1,396,776,000	$1,396,606,000
Debt Instrument Fair Value	$1,489,700,000	$1,502,000,000

Business_Segment_Information_D

Business Segment Information (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Segment Reporting, Revenue Reconciling Item [Line Items]	'	'
Revenues	$29,176,362	$21,059,811
Segment Reporting Information [Line Items]	'	'
Operating Income (Loss)	159,616	299,440
Antitrust Settlements Gain	21,023	12,308
LIFO expense	-57,582	-1,167
Acquisition Related Intangibles Amortization	-5,958	-6,099
Warrants	-116,297	0
Employee severance, litigation and other	-4,302	-2,004
Other income	-597	-23
Interest expense, net	18,832	18,525
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Cumulative Effects of Changes in Accounting Principles, Noncontrolling Interest	141,381	280,938
Pharmaceutical Distribution [Member]	'	'
Segment Reporting, Revenue Reconciling Item [Line Items]	'	'
Revenues	28,622,591	20,599,048
Segment Reporting Information [Line Items]	'	'
Operating Income (Loss)	286,782	266,677
Other Segment [Member]	'	'
Segment Reporting, Revenue Reconciling Item [Line Items]	'	'
Revenues	604,132	505,050
Segment Reporting Information [Line Items]	'	'
Operating Income (Loss)	35,950	29,725
Intersegment Elimination [Member]	'	'
Segment Reporting, Revenue Reconciling Item [Line Items]	'	'
Revenues	-50,361	-44,287
Total Segments [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Operating Income (Loss)	$322,732	$296,402